-
-
-
-
-
-
-
InflaRx to Report Full Year 2024 Results on March 20 and Announces Participation in March Investor Conferences
-
-
-
-
-
-
-
InflaRx's (IFRX) MAA for Vilobelimab Under Review by the EMA
-
-
-
-
-
-
-
InflaRx to Present at the H.C. Wainwright 23rd Annual Global Investment Conference
-
-
-
-
21,361 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

